Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203136 | 0.98 | TDP1 (0.64) | TDP1MAPTRXFP1LPAR1ALOX5 | |
| SCHEMBL27409810 | 0.94 | TDP1 (0.66) | TDP1ALOX5HDAC1HDAC2ALDH1A1 | |
| SCHEMBL1788500 | 0.89 | TDP1 (0.68) | TDP1MAPTRXFP1LPAR1ALOX5 | |
| SCHEMBL7781081 | 0.89 | TDP1 (0.68) | TDP1MAPTRXFP1LPAR1ALOX5 | |
| SCHEMBL14445679 | 0.87 | LMNA (0.59) | MAPTRXFP1ALDH1A1FFAR1 | |
| SCHEMBL1345319 | 0.87 | LMNA (0.59) | MAPTRXFP1ALDH1A1FFAR1 | |
| SCHEMBL10702591 | 0.87 | LMNA (0.59) | MAPTRXFP1ALDH1A1FFAR1 | |
| SCHEMBL15529361 | 0.87 | LMNA (0.59) | MAPTRXFP1ALDH1A1FFAR1 | |
| SCHEMBL5945554 | 0.87 | LMNA (0.59) | MAPTRXFP1ALDH1A1FFAR1 | |
| SCHEMBL16672953 | 0.87 | LMNA (0.59) | MAPTRXFP1ALDH1A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | PTGER4, PTGER1, PTGER2 | TDP1 3347/4885MAPT 2797/4885RXFP1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.